Is COVID-19-Related Mucormycosis Now a Threat in Europe?

Emel Tahir; Özgür Kemal; Mustafa Aktaş; Aynur Atilla

doi:10.5152/ejra.2022.22059

Is COVID-19-Related Mucormycosis Now a Threat in Europe?

Abstract

The frequency of secondary infections has also increased following the ongoing coronavirus pandemic. We aimed to attract attention to the COVID-19-related mucormycosis, a highly mortal complication of COVID-19, and its treatment. A retrospective review of the patient database was performed after the pandemic declaration. These patients’ medical files, treatment charts, and radiological and histological data were examined. The study group consisted of three COVID-19-related mucormycosis patients. All three patients had uncontrolled diabetes. One patient had no previously diagnosed diabetes and died due to widespread mucor infection and severe ketoacidosis. In the other two patients, the diagnosis was made promptly by frozen examination, endoscopic debridement was performed, antifungal treatment was started immediately, and infection was controlled following strict blood sugar control. The widespread use of steroids, and uncontrolled diabetes, are major risk factors that make patients susceptible to mucormycosis. In patients with COVID-19, physicians should be cautious of the possibility of invasive fungal infection. In addition to debridement, an active interdisciplinary approach can help reduce mortality.

Keywords

References

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5-264.e8.
Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:105957.
Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. 2021;64(8):798-808.
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12): e405-e421.
Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: we should be prepared. J Mycol Med. 2020;30(2): 100971.
Ardi P, Daie-Ghazvini R, Hashemi SJ, et al. Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation. Microb Pathog. 2020;147:104382.
Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43.
Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-425.

Details

Primary Language

English

Subjects

Otorhinolaryngology

Journal Section

Case Report

Authors

Emel Tahir
0000-0002-5219-0542
Türkiye

Özgür Kemal
0000-0002-6419-6204
Türkiye

Mustafa Aktaş
0000-0003-4779-7582
Türkiye

Aynur Atilla
0000-0001-8027-1991
Türkiye

Publication Date

December 15, 2022

Submission Date

February 21, 2022

Acceptance Date

July 26, 2022

Published in Issue

Year 2022 Volume: 5 Number: 3

DOI

https://doi.org/10.5152/ejra.2022.22059

IZ

https://izlik.org/JA88RK46BB

Cite

RIS / Bibtex

APA

Tahir, E., Kemal, Ö., Aktaş, M., & Atilla, A. (2022). Is COVID-19-Related Mucormycosis Now a Threat in Europe? European Journal of Rhinology and Allergy, 5(3), 102-104. https://doi.org/10.5152/ejra.2022.22059

AMA

1.Tahir E, Kemal Ö, Aktaş M, Atilla A. Is COVID-19-Related Mucormycosis Now a Threat in Europe? Eur J Rhinol Allergy. 2022;5(3):102-104. doi:10.5152/ejra.2022.22059

Chicago

Tahir, Emel, Özgür Kemal, Mustafa Aktaş, and Aynur Atilla. 2022. “Is COVID-19-Related Mucormycosis Now a Threat in Europe?”. European Journal of Rhinology and Allergy 5 (3): 102-4. https://doi.org/10.5152/ejra.2022.22059.

EndNote

Tahir E, Kemal Ö, Aktaş M, Atilla A (December 1, 2022) Is COVID-19-Related Mucormycosis Now a Threat in Europe? European Journal of Rhinology and Allergy 5 3 102–104.

IEEE

[1]E. Tahir, Ö. Kemal, M. Aktaş, and A. Atilla, “Is COVID-19-Related Mucormycosis Now a Threat in Europe?”, Eur J Rhinol Allergy, vol. 5, no. 3, pp. 102–104, Dec. 2022, doi: 10.5152/ejra.2022.22059.

ISNAD

Tahir, Emel - Kemal, Özgür - Aktaş, Mustafa - Atilla, Aynur. “Is COVID-19-Related Mucormycosis Now a Threat in Europe?”. European Journal of Rhinology and Allergy 5/3 (December 1, 2022): 102-104. https://doi.org/10.5152/ejra.2022.22059.

JAMA

1.Tahir E, Kemal Ö, Aktaş M, Atilla A. Is COVID-19-Related Mucormycosis Now a Threat in Europe? Eur J Rhinol Allergy. 2022;5:102–104.

MLA

Tahir, Emel, et al. “Is COVID-19-Related Mucormycosis Now a Threat in Europe?”. European Journal of Rhinology and Allergy, vol. 5, no. 3, Dec. 2022, pp. 102-4, doi:10.5152/ejra.2022.22059.

Vancouver

1.Emel Tahir, Özgür Kemal, Mustafa Aktaş, Aynur Atilla. Is COVID-19-Related Mucormycosis Now a Threat in Europe? Eur J Rhinol Allergy. 2022 Dec. 1;5(3):102-4. doi:10.5152/ejra.2022.22059